Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

496 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma.
Aleman A, Upadhyaya B, Tuballes K, Kappes K, Gleason CR, Beach K, Agte S, Srivastava K; PVI/Seronet Study Group; Van Oekelen O, Barcessat V, Bhardwaj N, Kim-Schulze S, Gnjatic S, Brown B, Cordon-Cardo C, Krammer F, Merad M, Jagannath S, Wajnberg A, Simon V, Parekh S. Aleman A, et al. Among authors: jagannath s. Cancer Cell. 2021 Nov 8;39(11):1442-1444. doi: 10.1016/j.ccell.2021.09.015. Epub 2021 Oct 19. Cancer Cell. 2021. PMID: 34706273 Free PMC article. No abstract available.
Adverse drug reaction: pomalidomide-induced liver injury.
Veluswamy RR, Ward SC, Yum K, Abramovitz RB, Isola LM, Jagannath S, Parekh S. Veluswamy RR, et al. Among authors: jagannath s. Lancet. 2014 Jun 21;383(9935):2125-6. doi: 10.1016/S0140-6736(14)61030-8. Lancet. 2014. PMID: 24953475 No abstract available.
The effect of novel therapies in high-molecular-risk multiple myeloma.
Lancman G, Tremblay D, Barley K, Barlogie B, Cho HJ, Jagannath S, Madduri D, Moshier E, Parekh S, Chari A. Lancman G, et al. Among authors: jagannath s. Clin Adv Hematol Oncol. 2017 Nov;15(11):870-879. Clin Adv Hematol Oncol. 2017. PMID: 29200420 Free PMC article. Review.
Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Chari A, Lonial S, Mark TM, Krishnan AY, Stockerl-Goldstein KE, Usmani SZ, Londhe A, Etheredge D, Fleming S, Liu B, Ukropec J, Lin TS, Jagannath S, Nooka AK. Chari A, et al. Among authors: jagannath s. Cancer. 2018 Nov 15;124(22):4342-4349. doi: 10.1002/cncr.31706. Epub 2018 Nov 5. Cancer. 2018. PMID: 30395359 Free PMC article. Clinical Trial.
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2.
Barley K, Sanchez L, Cho HJ, Parekh S, Madduri D, Richter J, Isola L, Goldstein T, Dhadwal A, Zarychta K, Sanchez GM, Catamero D, Verina D, Florendo E, Yum MH, La L, Gullie J, Chan E, Jagannath S, Chari A. Barley K, et al. Among authors: jagannath s. Am J Hematol. 2020 Feb;95(2):E51-E54. doi: 10.1002/ajh.25695. Epub 2019 Dec 22. Am J Hematol. 2020. PMID: 31814152 Free article. Clinical Trial. No abstract available.
496 results